Peakdale Molecular Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Peakdale Molecular Ltd. - overview
Established
1992
Location
-, -, UK
Primary Industry
Pharmaceuticals
About
Peakdale Molecular Ltd. is a UK-based contract research organization specializing in drug discovery and development services across various therapeutic areas, providing expert solutions to biopharmaceutical and academic clients. Founded in 1992 in the UK, Peakdale Molecular Ltd. focuses on drug discovery services, including chemistry and biology.
The firm's acquisition by Concept Life Sciences in July 2014, a portfolio company of Equistone Partners Europe, marked a pivotal moment in its business strategy. The company operates from its headquarters in Derbyshire, UK. While specific information about the founder is not detailed, the firm has successfully executed 2 total deals, with the most recent deal occurring on July 7, 2014. The company has raised a total of GBP 1.
000 mn, with the latest funding round led by Solon Ventures. Peakdale Molecular Ltd. provides a wide array of services within the drug discovery and development arena, including expertise in Chemistry, Biology, ADME/DMPK, and Toxicology. Their integrated solutions aim to support the entire drug development lifecycle, catering to a diverse clientele that includes biopharmaceutical firms, academic institutions, and public health organizations.
The company specializes in high-throughput screening, lead optimization, and pharmacokinetic profiling to enhance the efficacy and safety of therapeutic candidates. In the most recent financial year of 2020, Peakdale Molecular Ltd. reported revenue of GBP 0. 0 mn and an EBITDA of GBP 0.
0 mn for 2021, reflecting its focus on service contracts that foster long-term partnerships with clients in the pharmaceutical and biotechnology sectors. Peakdale Molecular Ltd. aims to expand its reach in the drug discovery market by introducing new innovative services tailored to client needs, with plans to enter additional markets in Europe and North America by 2025. The recent funding of GBP 1.
000 mn will support these initiatives, enhancing the company's service capabilities and operational infrastructure.
Current Investors
Equistone Partners Europe, Concept Life Sciences Limited
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.peakdale.co.uk
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Peakdale Molecular Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Peakdale Molecular Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.